FDA-Approved Oligonucleotide Therapies in 2017

2002, A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS, Am. J. Ophthalmol., 133, 467

Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121

Eaton, 1997, The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets, Curr. Opin. Chem. Biol., 1, 10, 10.1016/S1367-5931(97)80103-2

Ng, 2006, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov., 5, 123, 10.1038/nrd1955

Ruckman, 1998, 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain, J. Biol. Chem., 273, 20556, 10.1074/jbc.273.32.20556

Jellinek, 1994, Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor, Biochemistry, 33, 10450, 10.1021/bi00200a028

Gragoudas, 2004, Pegaptanib for neovascular age-related macular degeneration, N. Engl. J. Med., 351, 2805, 10.1056/NEJMoa042760

D’Amico, 2005, VEGF inhibition study in ocular neovascularization (VISION): Second year efficacy data, Invest. Ophthalmol. Vis. Sci., 46, 2309

http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/modernmedicine/modern-medicine-news/valeant-acquires-eyetech.

Raal, 2010, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial, Lancet, 375, 998, 10.1016/S0140-6736(10)60284-X

Besseling, 2015, Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014), Atherosclerosis, 241, 597, 10.1016/j.atherosclerosis.2015.06.011

Crooke, 2005, An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis, J. Lipid Res., 46, 872, 10.1194/jlr.M400492-JLR200

De Mesmaeker, 1995, Antisense oligonucleotides, Acc. Chem. Res., 28, 366, 10.1021/ar00057a002

Davidson, 2000, APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation, Annu. Rev. Nutr., 20, 169, 10.1146/annurev.nutr.20.1.169

Mahley, R. Biochemistry and Physiology of Lipid and Lipoprotein Metabolism. In Principles and Practice of Endocrinology and Metabolism, Third Edition, K.L. Becker, ed. (Lippincott Williams and Wilkins).

McGowan, 2012, Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy, PLoS ONE, 7, e49006, 10.1371/journal.pone.0049006

Stein, 2012, Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease, Circulation, 126, 2283, 10.1161/CIRCULATIONAHA.112.104125

Thomas, 2013, Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial, J. Am. Coll. Cardiol., 62, 2178, 10.1016/j.jacc.2013.07.081

Excerpted from: Stein, C.A. (2016). Eteplirsen approved for Duchenne muscular dystrophy: The FDA faces a difficult choice. Mol. Ther. 24, 1884–1885.

Robinson-Hamm, 2016, Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy, Hum. Genet., 135, 1029, 10.1007/s00439-016-1725-z

Mendell, 2013, Eteplirsen for the treatment of Duchenne muscular dystrophy, Ann. Neurol., 74, 637, 10.1002/ana.23982

van Deutekom, 2013, Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy, Drug Discov. Today Ther. Strateg., 10, e149, 10.1016/j.ddstr.2013.04.001

Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3

Mendell, 2016, Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy, Ann. Neurol., 79, 257, 10.1002/ana.24555

Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol., 8, 918, 10.1016/S1474-4422(09)70211-X

Aartsma-Rus, 2014, Translational and regulatory challenges for exon skipping therapies, Hum. Gene Ther., 25, 885, 10.1089/hum.2014.086

Carrol. J. UPDATED: The FDA decides that it can’t decide yet on Sarepta’s eteplirsen. http://www.fiercebiotech.com/fda-decides-it-can-t-decide-yet-sarepta-s-eteplirsen.

Feuerstein, A. Sarepta, FDA compromise on plan to secure Duchenne drug approval. The Street, June 7, 2016. https://www.thestreet.com/story/13598536/1/sarepta-fda-compromise-on-plan-to-secure-duchenne-drug-approval.html.

Editorial. Where’s the drug, FDA? The Wall Street Journal, July 5, 2016. http://www.wsj.com/articles/wheres-the-drug-fda-1467413266.

Harper, M. Approving a muscular dystrophy drug ignites a civil war at the FDA. Forbes, September 20, 2016. https://www.forbes.com/sites/matthewherper/2016/09/20/approving-a-muscular-dystrophy-drug-ignites-civil-war-at-the-fda/.

Excerpted from: Stein, C., Castanotto, D., Krishnan, A., and Nikolaenko, L. (2016). Defibrotide (Defitelio): A new addition to the stockpile of Food and Drug Administration-approved oligonucleotide drugs. Mol. Ther. Nucleic Acids 5, e346.

Pescador, 2013, Defibrotide: properties and clinical use of an old/new drug, Vascul. Pharmacol., 59, 1, 10.1016/j.vph.2013.05.001

Benimetskaya, 2008, Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease, Blood, 112, 4343, 10.1182/blood-2008-04-149682

Valla, 2016, Sinusoidal obstruction syndrome, Clin. Res. Hepatol. Gastroenterol., 40, 378, 10.1016/j.clinre.2016.01.006

Dalle, 2016, Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment, Biol. Blood Marrow Transplant., 22, 400, 10.1016/j.bbmt.2015.09.024

Fan, 2014, Sinusoidal obstruction syndrome (hepatic veno-occlusive disease), J. Clin. Exp. Hepatol., 4, 332, 10.1016/j.jceh.2014.10.002

DeLeve, 2003, Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 284, G1045, 10.1152/ajpgi.00526.2002

DeLeve, 2002, Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease), Semin. Liver Dis., 22, 27, 10.1055/s-2002-23204

Dignan, 2013, BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation, Br. J. Haematol., 163, 444, 10.1111/bjh.12558

Mohty, 2015, Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT), Bone Marrow Transplant., 50, 781, 10.1038/bmt.2015.52

Richardson, 2016, Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure, Blood, 127, 1656, 10.1182/blood-2015-10-676924

Cheuk, 2015, Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation, Cochrane Database Syst. Rev., 5, CD009311

Akimoto, 2003, Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta, Am. J. Physiol. Cell Physiol., 284, C371, 10.1152/ajpcell.00193.2002

Bikfalvi, 1997, Biological roles of fibroblast growth factor-2, Endocr. Rev., 18, 26

Basilico, 1992, The FGF family of growth factors and oncogenes, Adv. Cancer Res., 59, 115, 10.1016/S0065-230X(08)60305-X

Seghezzi, 1998, Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis, J. Cell Biol., 141, 1659, 10.1083/jcb.141.7.1659

Jones, 2004, Polyanions and the proteome, Mol. Cell. Proteomics, 3, 746, 10.1074/mcp.R400008-MCP200

Bashkin, 1989, Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules, Biochemistry, 28, 1737, 10.1021/bi00430a047

Vlodavsky, 1987, Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix, Proc. Natl. Acad. Sci. USA, 84, 2292, 10.1073/pnas.84.8.2292

Baird, 1987, Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response, Biochem. Biophys. Res. Commun., 142, 428, 10.1016/0006-291X(87)90292-0

Powers, 2000, Fibroblast growth factors, their receptors and signaling, Endocr. Relat. Cancer, 7, 165, 10.1677/erc.0.0070165

Palomo, 2016, What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance, Blood, 127, 1719, 10.1182/blood-2015-10-676114

Bianchi, 1993, Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist, Eur. J. Pharmacol., 238, 327, 10.1016/0014-2999(93)90864-E

Francischetti, 2012, Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria, Arterioscler. Thromb. Vasc. Biol., 32, 786, 10.1161/ATVBAHA.111.240291

Eissner, 2002, Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide, Blood, 100, 334, 10.1182/blood.V100.1.334

Koehl, 2007, Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo, Cancer Biol. Ther., 6, 686, 10.4161/cbt.6.5.3959

Echart, 2009, The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity, Blood Coagul, Fibrinolysis., 20, 627, 10.1097/MBC.0b013e32832da1e3

Cella, 2001, Tissue factor pathway inhibitor release induced by defibrotide and heparins, Clin. Appl. Thromb. Hemost., 7, 225, 10.1177/107602960100700308

Coccheri, 1988, Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man, Eur. J. Clin. Pharmacol., 35, 151, 10.1007/BF00609244

Hua, 2010, Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model, Genes Dev., 24, 1634, 10.1101/gad.1941310

MDA. Spinal muscular atrophy. http://www.mda.org/disease/spinal-muscular-atrophy/types.